

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-032025-0001476

Date: 3.4.25

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000, please see response below.

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq) - 2
- Durvalumab (Imfinzi) - 0
- Nivolumab (Opdivo) - 0
- Pembrolizumab (Keytruda) - 6
- Chemotherapy - 25
- Radiotherapy - Not treated at this Trust
- Chemotherapy AND Radiotherapy - Not treated at this Trust
- Osimertinib - 5

Q2. How many patients were treated in the past 3 months for gastric cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin) - 2
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) - 0
- Lonsurf (Trifluridine - tipiracil) - 0
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - 1
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - 0
- Any other systemic anti-cancer therapy - 7
- Palliative care only - Not recorded in cEPMA system
- Zolbetuximab (Vyloy) 0

Q3 How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with: - Not recorded in a format that allows this patient group to be differentiated.

- CAPOX (Capecitabine with Oxaliplatin)
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
- Lonsurf (Trifluridine - tipiracil)
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Zolbetuximab (Vyloy)

- Any other systemic anti-cancer therapy
- Palliative care only

Q4 How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction?

- 12 Gastric, unable to differentiate for GOJ patients

Q5. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma? - 0

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust